Back to homepage Areas of expertise

Pharma & Animal health

Our expertise in microbiology and molecular biology enables us to support the development of your candidates that contribute to the health of domestic animals or livestock through preventive or curative approaches. To ensure that your projects are carried out under the best possible conditions, our team will support you throughout your development, from the research phases to the monitoring of animal studies.

Who are you?
What are you looking for?

In the context of the development of your drug candidates aimed at improving animal health, you are seeking an in vitro services provider in microbiology and molecular biology to support your projects in the design and enhancement of products at all stages. Smaltis is the ideal company to meet your needs, offering high scientific expertise and a customized approach.

The products you plan to develop

  • Antibiotics
  • Antifungals
  • Antimicrobial peptides
  • Antibacterial antibodies
  • Vaccine components
  • Other molecules for anti-infectious purposes
  • Other compounds acting on animal health through the microbiome
  • Disinfectant products

The approaches you work on

Are you working on the anti-infectious axis, on modulating a microbiome, or on developing compounds used for animal vaccination? Whatever strategy you employ to bring benefits to animal health, the Smaltis team, along with its expertise, knowledge, and technologies, is at your disposal to facilitate and successfully execute your projects.

At what stage are you?

DEVELOPMENT STAGES 1

RESEARCH & SELECTION

2

PROOF OF CONCEPT/EFFICACY

3

BIOPROCESSES

4

ANIMAL STUDIES

OUR SERVICES

Screening of candidates,
Characterization of products in terms of functionality and safety

Understanding of action mechanisms,
Biomarker research

Development and optimization of bioprocesses,
Supply and optimization of strain-producing compounds

Support for animal studies through in vitro monitoring of samples,
Assistance in data analysis

Why choose Smaltis?

Our services and support enable you to supply, enhance, and secure your data within a rigorous scientific framework. We have been working for several years on various projects in animal health, and our teams of scientists are capable of discussing your objectives and recommending the most suitable and relevant manipulations for your needs. You can rely on Smaltis for complete project management, adaptation to your requirements, and guaranteed traceability of the experiments conducted.

Get in touch!

They trust us

Testimonials and references

Delphine GALLAND
Head of Preclinical Clinical Studies
VETOQUINOL

For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.

Jérôme SCHMEISSER and Christelle IACONIS
Biology lab manager
and Scientist
DSM-FIRMENICH

In the context of our developments in animal health dietary supplements, we turned to SMALTIS to assess the impact of our products on the expression of genes of interest in different tissues. The molecular biology expertise of SMALTIS allows us to rely on this laboratory, whose qualitative results provide us with robust and reliable data. We also benefit from constructive exchanges with their teams to progress together throughout the project. SMALTIS thus constitutes a true extension of our R&D department, allowing us to focus on our own expertise while relying on this partner with whom we will continue to collaborate.

Pierre BELICHARD
CEO
ENTEROME

As part of the development of our candidate EB8018 designed to block bacteria expressing virulence factor FimH (a key inducer of the inflammatory cascade of the intestine, particularly in patients with Crohn disease), we have successively called upon the services of SMALTIS. In the preclinical phase, they first quantified in vitro the adhesion and invasion capacities of a collection of strains isolated from patients on a model of intestinal cell infection and then evaluated the impact of our molecule on these strains. The quality of the work performed, the level of expertise of the team combined with the ability to listen and adapt, led us to include SMALTIS as a service provider in our Phase 1b clinical study. The team developed a customized procedure to isolate and dissociate bacteria called "adherent" and "invasive" in intestinal biopsies, and then demonstrated the action of our EB8018 compound on these strains. SMALTIS continues to support the development of EB8018 in a phase 2a clinical trial.

Romain DAILLERE
Head of Preclinical Research - Co-founder
EVERIMMUNE

As part of the Oncobax®-AK project and the development of Live Biotherapeutic Products to potentiate the efficacy of cancer immunotherapies, we called upon Smaltis' services to characterize one of our candidate bacterial strains. The objective was to provide a complete file to the regulatory authorities regarding the characteristics of the strain, before initiating clinical studies. The Smaltis team worked hard to develop the protocols and test conditions necessary to determine the specificities of the strain of interest. The rigor shown by Smaltis' researchers, the quality and detail of the data transmitted, as well as the scientific relevance of the various characterization tests, allowed us to meet the regulatory requirements and to initiate the clinical trials with confidence. We are delighted to have collaborated with Smaltis.

News and articles

AMR Conference 8th edition

Smaltis is happy to participate to the 8th edition of AMR Conference in Basel from March 6th to 7th 2024, a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.

READ THE POST

The same… But better!

The year 2024 marks the 10th anniversary (already!) of the Smaltis adventure! 10 years of microbiology, 10 years of molecular biology, 10 years of passion, 10 years of twists and turns, 10 years of growth, 10 years of self-reflection, 10 years of continuous improvement, 10 years of scientific spirit, 10 years of ambition, 10 years of collaboration, 10 years of human relationships…

It was necessary to celebrate this milestone, and not just by blowing out the candles.

READ THE POST

The Polepharma Microbiomics Days

Smaltis is delighted to have participated in and sponsored, for the fourth consecutive year, the Polepharma Microbiomics Days, held in Rouen on November 22 and 23, 2023.

READ THE POST

The man who wanted to extend lifespan

Once upon a time, more than a century ago, Elie Metchnikoff hypothesized that health could be improved, and senility delayed by modulating the intestinal microbes thanks to bacteria present in yogurt. This zoologist and microbiologist was thus one of the first scientists to take an interest in gut microbiota and what we now call probiotics, the consumption of which he claimed helped to fight against aging.

This is the story of “the man who wanted to extend lifespan”.

READ THE POST

All our sincere wishes

In this new year that begins, let’s take the time…

Let’s take the time to extend our best wishes to you, from the bottom of our hearts. It seems essential to us, during these periods conducive to gratitude, to prioritize human relationships as the most important aspect of our lives.

READ THE POST